Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study.
Miguel Armengot-CarcellerMaría José Gómez-GómezCarmen García-NavalónEncarna Doménech-CamposNoelia Muñoz-FernándezAinhoa García-Lliberós de MiguelJaime Marco-AlgarraMarta Palop-CerveraAlfonso García PiñeroPublished in: American journal of rhinology & allergy (2020)
Omalizumab was effective for the treatment of patients with recalcitrant CRSwNP and mild asthma, even when AERD was present, by reducing NP size and improving QoL; treatment time was a key factor. SNOT-22 improvements were not explained by decreases in TPS, indicating that omalizumab may be effective in all patients, regardless of polyp size.